Welcome to HitGen

Capabilities & Services

Enabling Innovative Drug Discovery with Advanced Technologies

  • DEL for
    DEL for
  • DNA-encoded Library
    DNA-encoded Library
  • Fragment-based Drug Discovery
    FBDD/SBDD
  • Chemistry
    Chemistry
  • Bioscience
    Bioscience
  • Computational Sciences and Informatics
    Computational Sciences and Informatics
  • Structural Biology
    Structural Biology
  • Pre-clinical Studies
    Pre-clinical Studies
  • Clinical Development
    Clinical Development

Therapeutic Areas

Integrated One-stop Drug Discovery Platform   Accelerating Project with High Efficiency

  • Oncology and Immuno-oncology
    Oncology and Immuno-oncology
  • Inflammatory and Autoimmune Diseases
    Inflammatory and Autoimmune Diseases
  • Ophthalmology
    Ophthalmology
  • Infectious Diseases
    Infectious Diseases
  • Metabolic Diseases
    Metabolic Diseases
  • Cardiovascular Diseases
    Cardiovascular Diseases
HitGen Inc. is a rapidly developing biotech company
The discovery and development of novel medicines and agrochemicals
>1.2 Trillion

DNA encoded compounds

>6,000

novel drug/target complex structures for FBDD/SBDD

About Us

HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.


For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com.

For media inquiries: media@hitgen.com

For investor inquiries: investors@hitgen.com  

For business development: bd@hitgen.com  


Read More

Collaboration Partners

Latest News

  • 08 October 2024

    Pharma Peers Unite to Build DNA-Encoded Libraries

    Finding tools and hits for targets in drug discovery can feel like hunting for four leaf clovers in a blizzard. And researcher Sylvie Sakata was close to giving up on one discovery tool, DNA-encoded libraries, when a new consortium started to fall into place. Now this technology is garnering more interest for its potential to discover new molecular compounds, known as “hits,” to exponentially impact the early research efforts that can lead to potential new medicines.
    + Read More
  • 28 August 2024

    Infographic | HitGen FY2024H1 Report

    Infographic | HitGen FY2024H1 Report
    + Read More
  • 22 August 2024

    Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program

    CHENGDU, China, August 22, 2024 – Bridge Biotherapeutics ("Bridge", KQ288330), a clinical-stage biotech company, announced that it has entered into a joint research agreement with HitGen Inc. ("HitGen", SSE: 688222.SH), a Chinese drug discovery platform company. This collaboration builds on successful initial hit finding and identification work from HitGen’s DNA-encoded library (DEL), aiming to further develop the novel hits as promising drug candidates for cancer.
    + Read More
Investors

Latest Announcements,
Financial News and Stock Information

Read More

Thanks for reading!

For more details on how we can advance your innovative drug discovery projects
验证码
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information